Back to Journals » Drug Design, Development and Therapy » Volume 13

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Corrigendum]

Authors Abe M , Tsushima K, Sakayori M , Suzuki K , Ikari J, Terada J, Tatsumi K 

Received 31 January 2019

Accepted for publication 31 January 2019

Published 28 February 2019 Volume 2019:13 Pages 807—808


Abe M, Tsushima K, Sakayori M, et al. Drug Des Devel Ther. 2018;12:3369–3375.

On page 3372, last paragraph of “Results” section should read from “In Severe Group, patients who were able to continue nintedanib for more than 3 months (n = 4) exhibited significantly better prognosis compared to those who could not (n = 13) (P = 0.007) (Figure 6).” to “In Severe Group, patients who were able to continue nintedanib for more than 3 months (n = 13) exhibited significantly better prognosis compared to those who could not (n = 4) (P = 0.007) (Figure 6).”

Read the orginal article


Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.